Feedback
Settings

Settings

Goto Application

3,711 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(FPUGCISOLXNPPC-IOSLPCCCSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 372
1.WO/2025/250534T CELL TARGETS FOR TUBERCULOSIS VACCINES
WO - 04.12.2025
Int.Class A61K 39/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
04Mycobacterium, e.g. Mycobacterium tuberculosis
 Appl.No PCT/US2025/031027 Applicant THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Inventor DAVIS, Mark M.
The Mtb protein Rv2140c, specific peptide epitopes derived, and polynucleotide sequences encoding such polypeptides are disclosed herein as a useful TB antigen for generating a protective immune response to development of tuberculosis. In some embodiments the Rv2140c polypeptide or polynucleotide is formulated as a vaccine. In some embodiments the Rv2140c vaccine is administered to a naïve recipient. In some embodiments the Rv2140c vaccine is administered as a booster to a previously vaccinated to exposed individual. In some embodiments the previous vaccination is a BCG vaccination.
2.WO/2025/250751CIRCULAR RNA COMPOSITIONS AND METHODS
WO - 04.12.2025
Int.Class A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
 Appl.No PCT/US2025/031358 Applicant ORNA THERAPEUTICS, INC. Inventor EMMANUEL, Akinola
Circular RNA, along with related compositions, methods, and precursor RNA, are described herein. In some embodiments, the composition comprises a transfer vehicle and a circular RNA comprising a 3' self-spliced exon segment, a translation initiation element (TIE), an expression sequence encoding a chimeric antigen receptor (CAR), and a 5' self-spliced exon segment. In some embodiments, the transfer vehicle comprises an ionizable lipid disclosed herein. In some embodiments, the circular RNA and/or composition thereof has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life as compared to linear RNA. Also presented herein are methods and compositions for the manufacture and preparation of circularized RNAs, along with methods of administering said circular RNAs and related compositions to a subject in need thereof for treatment or prevention purposes.
3.WO/2025/250677COMPOSITIONS AND METHODS FOR CORRECTION OF TREX1 MUTATIONS
WO - 04.12.2025
Int.Class C12N 15/52
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
52Genes encoding for enzymes or proenzymes
 Appl.No PCT/US2025/031247 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor MINER, Jonathan
Compositions and methods for correction of RVCL-causing mutations in a TREX1 gene are provided.
4.WO/2025/242026CANCER VACCINES AND USES THEREOF
WO - 27.11.2025
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
 Appl.No PCT/CN2025/095665 Applicant EVEREST MEDICINES (CHINA) CO., LTD. Inventor XIE, Liang
Provided herein are nucleic acids, pharmaceutical compositions and vaccines that express two or more cancer antigens. Also provided herein are methods for treating a cancer.
5.20250361502Promoters And Compositions
US - 27.11.2025
Int.Class C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
 Appl.No 19265567 Applicant Oxford University Innovation Limited Inventor Hagan Bayley

The present invention relates to activatable promoters, as well as expression systems, vectors, delivery systems, reaction vessels, aqueous objects and compositions comprising said activatable promoters. The invention also provides compositions comprising assemblies and networks of aqueous objects comprising said activatable promoters. The invention additionally provides methods of expressing a transcript and methods of expressing a polypeptide using the activatable promoters of the invention. The invention further provides phospholipid mixtures, as well as aqueous objects and compositions comprising said phospholipid mixtures

6.WO/2025/244124METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER
WO - 27.11.2025
Int.Class C07H 21/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
02with ribosyl as saccharide radical
 Appl.No PCT/JP2025/018722 Applicant SUMITOMO CHEMICAL COMPANY, LIMITED Inventor TAKESHITA, Reo
The present invention provides a method for efficiently producing a nucleic acid oligomer, particularly a method for efficiently oxidizing a nucleic acid precursor that has a phosphite triester bond. Specifically, the present invention provides a method which is for producing, via the phosphoramidite method, a nucleic acid compound that has, at the 5' terminal, a nucleotide represented by formula (I) and in which a nucleic acid that has at least one phosphorothioate bond is produced, said method comprising a step for reacting: a precursor that has, at the 5' terminal, a phosphite triester bond represented by formula (II); an aromatic hydrocarbon or an aromatic heterocyclic compound that has a conjugate acid pKa of less than 5; and an oxidizing solution that contains iodine, pyridine, and water. [The substituents in formulas (I) and (II) are as defined in the description.]
7.WO/2025/244008MEASUREMENT METHOD, PROGRAM, AND HIGH-SPEED LIQUID CHROMATOGRAPH TANDEM MASS SPECTROMETER
WO - 27.11.2025
Int.Class G01N 27/62
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
27Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
62by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
 Appl.No PCT/JP2025/018148 Applicant SHIMADZU CORPORATION Inventor KUNISAWA, Akihiro
A method for measuring a creatinine correction value of a nucleoside according to the present disclosure includes a step (S10) for temporally separating a component, a step (S12) for acquiring a chromatogram of an ion derived from each component, a step (S14) for acquiring a nucleoside measurement value on the basis of a chromatogram of an ion of the nucleoside, a step (S16) for acquiring a creatinine measurement value on the basis of a chromatogram of a product ion other than the product ion having the highest ionic strength of creatinine, and a step (S18) for calculating a creatinine correction value of the nucleoside.
8.4653532ADVANCED RNA TARGETING (ARNATAR)
EP - 26.11.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No 25205877 Applicant ARNATAR THERAPEUTICS INC Inventor LIANG XUEHAI
Disclosed herein are Advanced RNA Targeting (ARNATAR) oligomeric compounds, thoughtfully designed compounds for inhibiting gene expression through the RISC pathway. Such compounds are useful in methods for reducing expression of certain genes, many of which are associated with a variety of diseases and disorders.
9.4653447MODIFIED NUCLEOSIDE MONOMER AND DOUBLE-STRANDED RIBONUCLEIC ACID
EP - 26.11.2025
Int.Class C07H 15/26
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
26Acyclic or carbocyclic radicals, substituted by hetero rings
 Appl.No 24744340 Applicant CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD Inventor SU XIAOYE
The present disclosure relates to the field of biomedicine, and in particular to a modified nucleoside monomer compound, a double-stranded ribonucleic acid containing same with reduced off-target effects or improved activity of inhibiting gene expression, and use for manufacturing a medicament for inhibiting target gene expression in mammalian cells and a composition comprising the medicament.
10.WO/2025/240509LIGATION OF POLYNUCLEOTIDES BY LIGASES AND SCREENING METHODS THEREOF
WO - 20.11.2025
Int.Class C12Q 1/25
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
25involving enzymes not classifiable in groups C12Q1/26-C12Q1/7097
 Appl.No PCT/US2025/029185 Applicant CODEXIS, INC. Inventor BIMM, Alexander, Jacob
The present disclosure provides a method of predicting a reaction condition activity profile of a ligase for a ligase substrate by Gaussian Process Regression using activity data obtained for different reaction conditions. Further provided is a method of screening a plurality of ligases for activity on a ligase substrate for identifying ligases active on the ligase substrate.
# -